Opko Renal, LLC

Opko Ireland Global Holdings, Limited

Proventiv Therapeutics, LLC

Cytochroma Inc.

Eirgen Pharma Ltd.

Opko Health, Inc.

Opko IP Holdings Ii, Inc.

Opko Ireland Global Hodlings, Ltd.

Eric J Messner

Charles W Bishop

Keith H Crawford

P Martin Petkovich

Jay A White

Samir P Tabash

Sammy Asiamah Agudoawu

Christian F Helvig

Martin Petkovich

Joel Z Melnick

Sammy A Agudoawu

Martin P Petkovich

Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D, 25-hydroxyvitamin D, or a combination of 25-hydroxyvitamin Dand 25-hydroxyvitamin D, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D, 25-hydroxyvitamin D, or a combination of 25-hydroxyvitamin Dand 25-hydroxyvitamin D.

Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin Dand 25-hydroxyvitamin D

A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering 25-hydroxyvitamin Dwith or without 25-hydroxyvitamin Dand, as necessary, 1,25-dihydroxyvitamin Das a Vitamin D hormone replacement therapy.

Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.

Methods and compositions for reducing parathyroid levels

The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D, and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin Dfor 25-hydroxyvitamin D repletion and/or maintenance.

Method of treating and preventing secondary hyperparathyroidism

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Methods for controlled release oral dosage of a vitamin D compound

Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3

[object Object]

Method for treating secondary hyperparathyroidism in CKD

Method for controlled release oral dosage of a vitamin D compound

Growing community of inventors

Lake Forest, IL, United States of America

Eric J Messner